VRTX: second_quarter 2026 lobbying report

{"url":"https://lda.gov/api/v1/filings/af35af92-3276-4307-a9c3-701d463331ab/","filing_uuid":"af35af92-3276-4307-a9c3-701d463331ab","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/af35af92-3276-4307-a9c3-701d463331ab/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Mathew Lapinski","dt_posted":"2026-07-17T10:36:51-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"800 North Capitol Street, NW, Suite 800","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20002","registrant":{"id":400531586,"url":"https://lda.gov/api/v1/registrants/400531586/","house_registrant_id":null,"name":"CROSSROADS STRATEGIES, LLC","description":"lobbying firm","address_1":"800 North Capitol Street, NW, Suite 800","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20002","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MATHEW LAPINSKI","contact_telephone":"+1 202-559-0170","dt_updated":"2026-07-30T15:56:39.212913-04:00"},"client":{"id":56149,"url":"https://lda.gov/api/v1/clients/56149/","client_id":56149,"name":"VERTEX PHARMACEUTICALS INCORPORATED","general_description":"biopharmaceutical company","client_government_entity":null,"client_self_select":false,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-06-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143773,"prefix":"ms","prefix_display":"MS.","first_name":"CHERYL","nickname":null,"middle_name":"LYNN","last_name":"JAEGER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66496,"prefix":null,"prefix_display":null,"first_name":"JASON","nickname":null,"middle_name":"BENJAMIN","last_name":"VAN PELT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107303,"prefix":null,"prefix_display":null,"first_name":"BRITTANY","nickname":null,"middle_name":"JOHNSON","last_name":"HERNANDEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58561,"prefix":null,"prefix_display":null,"first_name":"MATHEW","nickname":null,"middle_name":null,"last_name":"LAPINSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151117,"prefix":"mr","prefix_display":"MR.","first_name":"STEPHEN","nickname":null,"middle_name":"THOMAS","last_name":"VOLJAVEC","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143856,"prefix":"ms","prefix_display":"MS.","first_name":"IVELISSE","nickname":null,"middle_name":"ALEXANDRA","last_name":"PORROA-GARCIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66499,"prefix":null,"prefix_display":null,"first_name":"CHRIS","nickname":null,"middle_name":"J","last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about precision medicine.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143773,"prefix":"ms","prefix_display":"MS.","first_name":"CHERYL","nickname":null,"middle_name":"LYNN","last_name":"JAEGER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66496,"prefix":null,"prefix_display":null,"first_name":"JASON","nickname":null,"middle_name":"BENJAMIN","last_name":"VAN PELT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107303,"prefix":null,"prefix_display":null,"first_name":"BRITTANY","nickname":null,"middle_name":"JOHNSON","last_name":"HERNANDEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58561,"prefix":null,"prefix_display":null,"first_name":"MATHEW","nickname":null,"middle_name":null,"last_name":"LAPINSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151117,"prefix":"mr","prefix_display":"MR.","first_name":"STEPHEN","nickname":null,"middle_name":"THOMAS","last_name":"VOLJAVEC","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143856,"prefix":"ms","prefix_display":"MS.","first_name":"IVELISSE","nickname":null,"middle_name":"ALEXANDRA","last_name":"PORROA-GARCIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66499,"prefix":null,"prefix_display":null,"first_name":"CHRIS","nickname":null,"middle_name":"J","last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151117,"prefix":"mr","prefix_display":"MR.","first_name":"STEPHEN","nickname":null,"middle_name":"THOMAS","last_name":"VOLJAVEC","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143856,"prefix":"ms","prefix_display":"MS.","first_name":"IVELISSE","nickname":null,"middle_name":"ALEXANDRA","last_name":"PORROA-GARCIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66499,"prefix":null,"prefix_display":null,"first_name":"CHRIS","nickname":null,"middle_name":"J","last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143773,"prefix":"ms","prefix_display":"MS.","first_name":"CHERYL","nickname":null,"middle_name":"LYNN","last_name":"JAEGER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66496,"prefix":null,"prefix_display":null,"first_name":"JASON","nickname":null,"middle_name":"BENJAMIN","last_name":"VAN PELT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107303,"prefix":null,"prefix_display":null,"first_name":"BRITTANY","nickname":null,"middle_name":"JOHNSON","last_name":"HERNANDEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58561,"prefix":null,"prefix_display":null,"first_name":"MATHEW","nickname":null,"middle_name":null,"last_name":"LAPINSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Policies impacting the manufacturing pharmaceutical products including tariffs.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143773,"prefix":"ms","prefix_display":"MS.","first_name":"CHERYL","nickname":null,"middle_name":"LYNN","last_name":"JAEGER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151117,"prefix":"mr","prefix_display":"MR.","first_name":"STEPHEN","nickname":null,"middle_name":"THOMAS","last_name":"VOLJAVEC","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}